## Abstract Interleukin‐1 (IL‐1) is considered to be involved in the pathogenesis of Graves' disease. The aim of this study was to test whether the IL‐1‐β gene promoter region and exon 5 and IL‐1 receptor antagonist (IL‐1Ra) gene intron 2 polymorphisms could be useful genetic markers for susceptibi
Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer
✍ Scribed by Ming-Hsui Tsai; Wen-Chi Chen; Chang-Hai Tsai; Liang-Wen Hang; Fuu-Jen Tsai
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 101 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0887-8013
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We aimed to evaluate whether polymorphisms of the interleukin‐4 (IL‐4) gene promoter and intron 3 regions, and polymorphisms of the IL‐1 beta gene promoter and exon 5 regions are associated with oral cancer. This study included 130 patients with oral cancer and 105 age‐matched healthy controls who lived in the same area as the patients. Each genetic polymorphism was typed by polymerase chain reaction (PCR)‐based restriction analysis. We then compared the genotype distribution and allelic frequencies of each polymorphism between the oral cancer patients and the controls. The CC homozygote genotype of the IL‐4 gene promoter −590 region differed significantly between the patients with oral cancer and the controls (odds ratio (OR)=6.0, 95% confidence interval (CI)=1.2−30.7, chi‐square test, P=0.044). No significant difference in either the genotype distribution or the allelic frequencies of the IL‐1 beta gene polymorphisms was observed between patients with oral cancer and controls. The IL‐4 gene −590 C/T polymorphism is associated with oral cancer and is a suitable genetic marker for screening for oral cancer. However, whether the −590 C/T polymorphism of the IL4 gene plays a role in oral cancer remains unclear. Further substantiation based on larger patient samples is needed. J. Clin. Lab. Anal. 19:93–98, 2005. © 2005 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Asthma is an airway hyperresponsive disease characterized by the expression of multiple inflammatory genes, including cytokines. Interleukin‐I and interleukin‐10 (IL‐1 and IL‐10) are cytokines that might play a role in the process of inflammation and are therefore considered to be invol
## Abstract Chronic obstructive pulmonary disease (COPD) is a multifactorial disorder characterized by irreversible airflow obstruction due to chronic inflammation. Hence, the gene encoding the anti‐inflammatory cytokine IL 11 is a good candidate for being involved in the genetic predisposition to
## Abstract Interleukin‐18 (IL‐18)‐656T/G, ‐607A/C, and ‐137C/G promoter polymorphisms had been reported associated with Kawasaki disease (KD). An IL‐18 genetic A/C polymorphism at coding position 105 (rs549908) has been linked with asthma, rheumatoid, and systemic lupus erythematosus. We tested a
## Abstract Lung cancer is one of the leading causes of cancer death worldwide. Tobacco smoking is the main risk factor for lung cancer. Less than 20% of smokers develop lung cancer in their lifetime, however, indicating individual variations in lung cancer risk. Pro‐inflammatory cytokines produced
Polymorphic variations may affect the rate of gene transcription, the stability of the mRNA, or the quantity and activity of the resulting protein. In this study we evaluated the association between the interleukin-1B C-31T, catechol-O-methyltransferase Val158Met, and thymidylate synthase (TS) 1494d